Cm Life Sciences II (CMII)

Sector - SPAC

IPO Profile

About company

They are a newly organized blank check company. While they may pursue an initial business combination target in any industry, sector or geographic region, they intend to capitalize on their management team’s background and experience to identify promising opportunities in the life sciences sector. Their team intends to leverage the strong life sciences knowledge base and public and private market experience of their sponsor with the goal of executing a successful business combination in the life sciences sector. Their sponsor is an affiliate of Eli Casdin, founder and Chief Investment Officer of Casdin Capital, and of Keith Meister, founder and Chief Investment Officer of Corvex Management, two leading investment firms. CM Life Sciences II has a focused acquisition strategy. They believe that the rise in both the number and quality of companies entering the genomics space today presages significant consolidation and restructuring. Their comprehensive understanding of the science, strong ties to the industry, and broad experience guiding public companies gives them a competitive advantage to help shape, and profit from, this key moment in the maturation of the industry.
CEO CFO
-
Employees Founded
3 2020

Contacts

Web page:

IPO information

Filed Date
Status Filed
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)
10
10
0
0
0
Price Low Price High Priced Open 1st day Close 1st day

Shares & Volumes

Shares Initial (MM) 20
Shares Revised (MM) -
Expected offer amount (MM) $200
Realized offer amount(MM) -

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) -
Net Income (Loss) (MM) -

Voting

What do you think will happen with the GLSI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes:
Underwriters
CO-Managers

Sector: SPAC